{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:47Z","timestamp":1790286947823,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bristol Meyers Squibb"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Apexigen"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jaad.2018.10.062","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T12:05:29Z","timestamp":1541246729000},"page":"990-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management"],"prefix":"10.1016","volume":"80","author":[{"given":"Emily","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Tomayko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jaad.2018.10.062_bib1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.062_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1758834014567470","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume":"7","author":"Sundar","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.062_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl_4","key":"10.1016\/j.jaad.2018.10.062_bib4","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.jaad.2018.10.062_bib5","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.062_bib6","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.062_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2018.10.062_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2018.10.062_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.10.062_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2018.10.062_bib11","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jaad.2018.10.062_bib12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2018.10.062_bib13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.062_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.062_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.062_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.10.062_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.062_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jdcr.2018.06.022","article-title":"Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin","volume":"4","author":"Coleman","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.062_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.annder.2017.11.005","article-title":"Two cases of granuloma annulare under anti-PD1 therapy","volume":"145","author":"Charollais","year":"2018","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.062_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CMR.0000000000000261","article-title":"Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.062_bib21","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1111\/jdv.14282","article-title":"Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab","volume":"32","author":"Page","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.062_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218328330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218328330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:49:01Z","timestamp":1759272541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218328330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0190962218328330"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.062","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}